Copyright: ©Author(s) 2026.
World J Hepatol. May 27, 2026; 18(5): 117441
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.117441
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.117441
Table 3 Prevalence of metabolic dysfunction-associated steatotic liver disease among the three study groups, n (%)
| Variable | Overt hypothyroidism (A) (n = 48) | Subclinical hypothyroidism (B) (n = 48) | Control (C) (n = 48) | P value | Paire-wise comparison |
| MASLD by ultrasound | |||||
| Non-MASLD | 13 (27.1) | 21 (43.8) | 45 (93.8) | < 0.001 | A vs B: 0.135 |
| MASLD | 35 (72.9) | 27 (56.3) | 3 (6.3) | A vs C: < 0.001 | |
| B vs C: < 0.001 | |||||
| MASLD by MRI | |||||
| Non-MASLD | 14 (29.2) | 21 (43.8) | 45 (93.8) | < 0.001 | A vs B: 0.203 |
| MASLD | 34 (70.8) | 27 (56.3) | 3 (6.3) | A vs C: < 0.001 | |
| B vs C: < 0.001 | |||||
- Citation: Sholkamy A, El-Meligui A, H Saad E, Amin S, Makram M, Elmansy N, Mousa S. Association between overt, subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging. World J Hepatol 2026; 18(5): 117441
- URL: https://www.wjgnet.com/1948-5182/full/v18/i5/117441.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i5.117441